Bryans J, Charlton P, Chicarelli-Robinson I, Collins M, Faint R, Latham C, Shaw I, Trew S
Xenova Limited, Slough, Berkshire, U.K.
J Antibiot (Tokyo). 1996 Oct;49(10):1014-21. doi: 10.7164/antibiotics.49.1014.
Two diketopiperazines, XR334 (1) and the novel compound XR330 (2), were isolated from the lyophilised biomass of an unidentified Streptomyces sp. Their structures were elucidated on the basis of spectroscopic studies and confirmed by chemical synthesis. Both compounds inhibited plasminogen activator inhibitor-1 activity in an amidolytic assay of tissue plasminogen activator mediated plasmin generation. Compound 1 also enhanced fibrinolysis ex vivo and protected against thrombus formation in the rat. These diketopiperazines represent the first low molecular weight inhibitors of plasminogen activator inhibitor-1, a physiological regulator of fibrinolysis.
从一株未鉴定的链霉菌冻干菌体中分离得到了两种二酮哌嗪,即XR334(1)和新型化合物XR330(2)。通过光谱学研究阐明了它们的结构,并通过化学合成得以证实。在组织型纤溶酶原激活物介导的纤溶酶生成的酰胺分解试验中,这两种化合物均能抑制纤溶酶原激活物抑制剂-1的活性。化合物1在体外也能增强纤维蛋白溶解,并能预防大鼠血栓形成。这些二酮哌嗪是纤溶酶原激活物抑制剂-1(一种纤维蛋白溶解的生理调节剂)的首批低分子量抑制剂。